182 related articles for article (PubMed ID: 8699235)
21. [Adoptive immunotherapy in patients with medulloblastoma by LAK cells].
Shimizu K; Tamura K; Yamada M; Okamoto Y; Miyao Y; Park K; Matsui Y; Hayakawa T; Takimoto H; Mogami H
No To Shinkei; 1989 Oct; 41(10):991-5. PubMed ID: 2605046
[TBL] [Abstract][Full Text] [Related]
22. Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients.
Boiardi A; Silvani A; Ruffini PA; Rivoltini L; Parmiani G; Broggi G; Salmaggi A
Cancer Immunol Immunother; 1994 Sep; 39(3):193-7. PubMed ID: 7923250
[TBL] [Abstract][Full Text] [Related]
23. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.
Merchant RE; Grant AJ; Merchant LH; Young HF
Cancer; 1988 Aug; 62(4):665-71. PubMed ID: 2840186
[TBL] [Abstract][Full Text] [Related]
24. The cellular immunotherapy of primary brain tumors.
Hayes RL
Rev Neurol (Paris); 1992; 148(6-7):454-66. PubMed ID: 1448666
[TBL] [Abstract][Full Text] [Related]
25. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model.
Marincola FM; Da Pozzo LF; Drucker BJ; Holder WD
Surgery; 1990 Nov; 108(5):919-29. PubMed ID: 2237773
[TBL] [Abstract][Full Text] [Related]
26. [Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation].
Nomura K; Fujioka T
Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):831-40. PubMed ID: 8320888
[TBL] [Abstract][Full Text] [Related]
27. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
Yoshida S; Takai N; Ono K; Saito T; Tanaka R
No To Shinkei; 1988 Feb; 40(2):119-25. PubMed ID: 3259433
[TBL] [Abstract][Full Text] [Related]
28. [The clinical study of local treatment of ocular malignant tumors with IL-2 LAK cells].
Yang L; Zhang J; Liang G
Zhonghua Yan Ke Za Zhi; 1995 May; 31(3):215-7. PubMed ID: 7555407
[TBL] [Abstract][Full Text] [Related]
29. Adoptive immunotherapy of intracerebral metastases in mice.
McCutcheon IE; Baranco RA; Katz DA; Saris SC
J Neurosurg; 1990 Jan; 72(1):102-9. PubMed ID: 2294169
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A
Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
[TBL] [Abstract][Full Text] [Related]
31. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
32. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
Wakizaka Y
Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
[TBL] [Abstract][Full Text] [Related]
33. Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study.
Ferlazzo G; Scisca C; Iemmo R; Cavaliere R; Quartarone G; Adamo V; Frazzetto G; Costa G; Melioli G
J Immunother; 1997 Mar; 20(2):158-63. PubMed ID: 9087388
[TBL] [Abstract][Full Text] [Related]
34. Short-duration in vitro interleukin-2-activated mononuclear cells for advanced cancer. A Hong Kong biotherapy pilot study trial.
Yeung AW; Pang YK; Tsang YC; Wong SW; Leung JS
Cancer; 1993 Jun; 71(11):3633-9. PubMed ID: 8387882
[TBL] [Abstract][Full Text] [Related]
35. Treatment of glioma with intratumoral instillation of autologous lymphocytes.
Bhagwati SN
Childs Nerv Syst; 1989 Feb; 5(1):38-40. PubMed ID: 2702675
[TBL] [Abstract][Full Text] [Related]
36. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma.
Dillman RO; Duma CM; Ellis RA; Cornforth AN; Schiltz PM; Sharp SL; DePriest MC
J Immunother; 2009; 32(9):914-9. PubMed ID: 19816190
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy with stimulated autologous lymphocytes in a case of a juvenile anaplastic glioma.
Thomas C; Schober R; Lenard HG; Lumenta CB; Jacques DB; Wechsler W
Neuropediatrics; 1992 Jun; 23(3):123-5. PubMed ID: 1641079
[TBL] [Abstract][Full Text] [Related]
38. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.
Kimura H; Yamaguchi Y
Cancer; 1997 Jul; 80(1):42-9. PubMed ID: 9210707
[TBL] [Abstract][Full Text] [Related]
39. Effect of lymphokine-activated killer cells with or without radiation therapy against malignant brain tumors.
Nakagawa K; Kamezaki T; Shibata Y; Tsunoda T; Meguro K; Nose T
Neurol Med Chir (Tokyo); 1995 Jan; 35(1):22-7. PubMed ID: 7700478
[TBL] [Abstract][Full Text] [Related]
40. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
